Tristel Regulatory News (TSTL)

Tristel plc

("Tristel" or the "Company")

AGM Statement and notice of results

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, will hold its Annual General Meeting at 11am today at Lynx Business Park, Fordham Road, Newmarket, Cambridgeshire CB8 7NY.

Paul Swinney, Chief Executive Officer, will address the meeting with the following update:

"As the half progressed, in all our geographical markets sales have picked-up well as hospitals have gradually returned to normal service levels for diagnostic procedures. We expect revenue to exceed £15m compared to £16.8m in the first half last year, noting revenue last year included a one-off sale of £0.9m to the NHS for Brexit-related inventory. This stock was released back to UK hospitals during this first half, creating a £1.8m period-on-period distortion. Overseas revenues are expected to account for 64% of worldwide sales during the half compared to 60% in the comparable period last year. Reducing our exposure to the UK NHS by growing our existing overseas businesses and entering new geographical markets is a key objective for the Company.

"Cash after the full-year dividend sits above £8m. Based on continued normalisation of hospital procedure numbers in the UK and elsewhere, which is clearly dependent on Covid-related updates, we are on track at this stage to be in line with market expectations for the year."

Notice of Results

The Company's unaudited interim results will be announced on 21 February 2022.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For further information please contact: